Study of Latiglutenase in T1D/CD Patients

Autori
Categoria Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
This is a phase 2, single-center prospective, double-blind, placebo-controlled, crossover study in Type 1 diabetes and celiac disease subjects attempting a GFD for at least one year prior to screening. Seropositive subjects (blood test confirmed at Visit 0) will be scheduled for a Screening Visit (Visit 1) whereas seronegative subjects will be discontinued from study participation (screen failures). Subjects who meet Visit 1 protocol enrollment criteria will be enrolled.
Epistemonikos ID: 0ae0cf4dbf059842d92bb331a0074fa32f9c8ee3
First added on: May 08, 2024